CLC bio funds further acceleration of bioinformatics product development
Aarhus, Denmark, July 3, 2007 — Today CLC bio, the world’s leading bioinformatics solution provider, announced that the company has entered an agreement, which ensures a significant amount of additional financing from local Danish private investors.
The group of private investors behind CLC bio has a capital base of more than 200 million USD and a goal of continually securing adequate resources and expertise for CLC bio to develop ground-breaking end-to-end bioinformatics solutions. These solutions will ensure that CLC bio becomes and stays the top choice in the biotech, agricultural, and pharmaceutical industries as well as at universities and hospitals all over the world.
Mr. Thomas Bruno, representing the group of new CLC bio Investors, states,
With very few resources, CLC bio has managed to develop an unequaled DNA, RNA, and protein sequence analysis solution. This, in conjunction with the fact that the solution addresses a rapidly growing market makes the company unique. Moreover, their well-developed and deliberate strategic and organizational planning is exceptional for such a young company. I am confident of the company’s tremendous potential, and I believe their bioinformatics solutions will dominate the industry within few years because customers achieve enormous rationalizations and savings. Which research- or business manager would pass up an opportunity like that?
The background for the financing agreement is very positive: An increasing number of CLC bio customers perceive the company as being able to solve most of their bioinformatics challenges - particularly areas related to DNA, RNA, and protein sequence analyses. Thus CLC bio experiences a sharp increase in the demand for developing even broader bioinformatics solutions than those offered presently. The extra financing ensures that these solutions will be developed even faster than originally planned.
Some of the new focus areas are end-to-end solutions for genomics research and solutions for handling the many computational challenges of the new generation of DNA sequencing techniques. In addition to this, present high-performance computing products and bioinformatics software solutions will be aggressively expanded.
About CLC bio
CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.
CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:
- Development of bioinformatics software and hardware based on the latest scientific findings
- User-friendly, integrated and intuitive cross-platform software solutions
- Continuous focus on customer needs and superior customer service
- Frequent product updates including the latest IT technologies and bioinformatics algorithms
- A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price
